- Home
- JUNS vs AVIR Comparison
JUNS vs AVIR Comparison
Compare JUNS & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- AVIR
- Stock Information
- Founded
- JUNS 2015
- AVIR 2012
- Country
- JUNS United States
- AVIR United States
- Employees
- JUNS N/A
- AVIR N/A
- Industry
- JUNS
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- JUNS
- AVIR Health Care
- Exchange
- JUNS NYSE
- AVIR Nasdaq
- Market Cap
- JUNS 281.4M
- AVIR 247.5M
- IPO Year
- JUNS 2024
- AVIR 2020
- Fundamental
- Price
- JUNS $4.40
- AVIR $3.37
- Analyst Decision
- JUNS
- AVIR Hold
- Analyst Count
- JUNS 0
- AVIR 1
- Target Price
- JUNS N/A
- AVIR $6.88
- AVG Volume (30 Days)
- JUNS 490.6K
- AVIR 528.5K
- Earning Date
- JUNS 02-11-2025
- AVIR 02-26-2025
- Dividend Yield
- JUNS N/A
- AVIR N/A
- EPS Growth
- JUNS N/A
- AVIR N/A
- EPS
- JUNS N/A
- AVIR N/A
- Revenue
- JUNS N/A
- AVIR N/A
- Revenue This Year
- JUNS N/A
- AVIR N/A
- Revenue Next Year
- JUNS N/A
- AVIR N/A
- P/E Ratio
- JUNS N/A
- AVIR N/A
- Revenue Growth
- JUNS N/A
- AVIR N/A
- 52 Week Low
- JUNS $3.86
- AVIR $2.75
- 52 Week High
- JUNS $19.51
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- AVIR 55.56
- Support Level
- JUNS N/A
- AVIR $3.11
- Resistance Level
- JUNS N/A
- AVIR $3.60
- Average True Range (ATR)
- JUNS 0.00
- AVIR 0.13
- MACD
- JUNS 0.00
- AVIR 0.00
- Stochastic Oscillator
- JUNS 0.00
- AVIR 53.17
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).